HC Wainwright Has Optimistic Outlook of IPA Q3 Earnings

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) – Research analysts at HC Wainwright lifted their Q3 2025 earnings per share estimates for shares of ImmunoPrecise Antibodies in a note issued to investors on Wednesday, December 11th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.06) for the quarter, up from their prior estimate of ($0.07). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for ImmunoPrecise Antibodies’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for ImmunoPrecise Antibodies’ FY2025 earnings at ($0.27) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.02) EPS, Q4 2026 earnings at ($0.01) EPS, FY2026 earnings at ($0.13) EPS and FY2027 earnings at $0.04 EPS.

ImmunoPrecise Antibodies Stock Performance

NASDAQ:IPA opened at $0.40 on Friday. The company has a market capitalization of $11.63 million, a price-to-earnings ratio of -0.52 and a beta of 0.06. The business has a 50 day moving average of $0.47 and a 200 day moving average of $0.72. The company has a debt-to-equity ratio of 0.36, a current ratio of 0.99 and a quick ratio of 0.82. ImmunoPrecise Antibodies has a 1-year low of $0.32 and a 1-year high of $2.60.

ImmunoPrecise Antibodies (NASDAQ:IPA) last issued its quarterly earnings results on Monday, September 16th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The firm had revenue of $3.85 million for the quarter, compared to the consensus estimate of $4.96 million. ImmunoPrecise Antibodies had a negative return on equity of 70.69% and a negative net margin of 114.50%.

Hedge Funds Weigh In On ImmunoPrecise Antibodies

A hedge fund recently raised its stake in ImmunoPrecise Antibodies stock. Renaissance Technologies LLC increased its stake in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 70.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 63,910 shares of the company’s stock after acquiring an additional 26,310 shares during the quarter. Renaissance Technologies LLC owned approximately 0.24% of ImmunoPrecise Antibodies worth $65,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 6.70% of the stock is owned by hedge funds and other institutional investors.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.